Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NGS-PTL

Financiado

Cerrado

Next Generation Sequencing platform for targeted Personalized Therapy of Leukemi...

Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia Hematological diseases are highly heterogeneous malignancies in the matter of the molecular mechanisms related to their development and progression. A considerable heterogeneity can be further observed within the same hematologica... ver más

31/10/2015

UNIBO

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

ALMA MATER STUDIORUM UNIVERSITA DI BOLOGNA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 9 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-10-31 No tenemos la información de la convocatoria

0% 77% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

UNIBO

0.00€ | Lider

FUNDACION DE INVESTIGACION D...

N.D. | Participante

MLL

N.D. | Participante

UNITO

N.D. | Participante

Proyectos interesantes

PDC2021-121243-I00

Medical Technol...

Data Science

102K€ Cerrado

PID2020-119537RB-I00

Medical Technol...

Data Science

242K€ Cerrado

EQC2018-004733-P

Medical Technol...

Data Science

171K€ Cerrado

CNS2023-143848

Medical Technol...

Data Science

200K€ Cerrado

RTC-2017-6685-1

Medical Technol...

Data Science

914K€ Cerrado

SAF2017-90781-REDI

Medical Technol...

Data Science

79K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

ALMA MATER STUDIORUM UNIVERSITA DI BOLOGNA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Hematological diseases are highly heterogeneous malignancies in the matter of the molecular mechanisms related to their development and progression. A considerable heterogeneity can be further observed within the same hematological disease at the inter-individual level, being reflected by different clinical outcomes and responses to treatment in different patients. Nowadays, the advent of high-throughput next generation sequencing (NGS) technologies that are revolutionizing genomics and transcriptomics by providing a single base resolution tool for a unified deep analysis of diseases complexity allows a fast and cost-efficient fine-scale assessment of the genetic variability hidden within cohorts of patients affected by the same leukemia. That being so, by potentially highlighting inter-individual differences that may play a role in the differential success of diverse therapeutic interventions, they promise to be crucial for selecting the most appropriate medical treatments. This project aims at developing a European Hematological/NGS platform of scientists for improving outcomes for therapeutic interventions on acute and chronic leukemias and at developing strategies to personalize treatments and tailor therapies to different stratified groups of leukemia patients, with the goal of optimizing their efficacy and safety through a deeper and deeper understanding of the influence of genetic alterations on leukemias pathogenesis and treatment response (i.e. personalized therapy). Moreover, the final aim will be the identification of novel prognostic biomarkers for acute and chronic leukemias, as well as of molecular biomarkers and/or genome-wide profiles for the assessment of minimal residual disease. The originality of this project is to perform systematic deep whole exome/transcriptome studies on well-clinically-characterized leukemia patients, by exploiting NGS technologies able to quickly produce data with a good cost-effectiveness and an unprecedented resolution.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores